Used to classify article posts by terms used for medical conditions. It’s mostly aimed at practitioners and physicians.

Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.

Authors: José Alexandre S Crippa, Guilherme Nogueira Derenusson, Thiago Borduqui Ferrari, et al
Journal of Psychopharmacology, January 2011

Animal and human studies indicate that cannabidiol (CBD), a major constituent of cannabis, has anxiolytic properties. However, no study to date has investigated the effects of this compound on human pathological anxiety and its underlying brain mechanisms. The aim of the prese…

Endocannabinoid involvement in endometriosis.

Authors: Natalia Dmitrieva, Hiroshi Nagabukuro, David Resuehr, Guohua Zhang, Stacy McAllister, et al
Pain, December 2010

Endometriosis is a disease common in women that is defined by abnormal extrauteral growths of uterine endometrial tissue and associated with severe pain. Partly because how the abnormal growths become associated with pain is poorly understood, the pain is difficult to alleviat…

Use of dronabinol (delta-9-THC) in autism: A prospective single-case-study with an early infantile autistic child.

Authors: René Kurz, Kurt Blaas
Cannabinoids, 21 November 2010

Objective: To evaluate the effectiveness of dronabinol (delta-9-THC) as supplementary therapy in a child with autistic disorder. Methods: A child who met the DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria for a diagnosis of autistic disorder and who to…

Smoked cannabis for chronic neuropathic pain: a randomized controlled trial.

Authors: Mark A. Ware, Tongtong Wang, Stan Shapiro, Ann Robinson, Thierry Ducruet, Thao Huynh, et al
CMAJ, 5 October 2010

BACKGROUND: Chronic neuropathic pain affects 1%-2% of the adult population and is often refractory to standard pharmacologic treatment. Patients with chronic pain have reported using smoked cannabis to relieve pain, improve sleep and improve mood. METHODS: Adults with post-tra…

Cannabis use in palliative care – an examination of the evidence and the implications for nurses.

Authors: Anita J Green, Kay De‐Vries
Journal of Clinical Nursing, September 2010

AIM AND OBJECTIVE: Examine the pharmaceutical qualities of cannabis including a historical overview of cannabis use. Discuss the use of cannabis as a clinical intervention for people experiencing palliative care, including those with life-threatening chronic illness such as mu…

Do cannabinoids have a therapeutic role in transplantation?

Authors: Mitzi Nagarkatti, Sadiye Amcaoglu Rieder, Venkatesh L. Hegde, Shunsuke Kanada, et al
Trends in Pharmacological Sciences, August 2010

Cannabinoids have emerged as powerful drug candidates for the treatment of inflammatory and autoimmune diseases due to their immunosuppressive properties. Significant clinical and experimental data on the use of cannabinoids as anti-inflammatory agents exist in many autoimmune…

Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis.

Authors: Celia J.A. Morgan, Tom P. Freeman, Gráinne L. Schafer, H. Valerie Curran
Neuropsychopharmacology, August 2010

Worldwide cannabis dependence is increasing, as is the concentration of Delta(9)-tetrahydrocannabinol (THC) in street cannabis. At the same time, the concentration of the second most abundant cannabinoid in street cannabis, cannabidiol (CBD), is decreasing. These two cannabino…

Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition.

Authors: María M Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, et al
Molecular Cancer, 22 July 2010

BACKGROUND: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small percentage of patients respond to these treatments and most o…

Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion.

Authors: Sarah K. Walsh, Claire Y. Hepburn, Kathleen A. Kane, Cherry L. Wainwright
British Pharmacological Society, July 2010

BACKGROUND AND PURPOSE: Cannabidiol (CBD) is a phytocannabinoid, with anti-apoptotic, anti-inflammatory and antioxidant effects and has recently been shown to exert a tissue sparing effect during chronic myocardial ischaemia and reperfusion (I/R). However, it is not known whet…

Cannabinoids, anxiety, and the periaqueductal gray.

Authors: Viviane M. Saito, Fabrício A. Moreira
Psychology & Neuroscience, June 2010

The use of Cannabis sativa by humans dates back several thousand years, for both its psychotomimetic and potential medicinal properties. As scientic research methods developed, the cannabinoids present in this herb were characterized, as well as their complex interface wi…

Posttraumatic Stress Symptom Severity and Marijuana Use Coping Motives: A Test of the Mediating Role of Non-Judgmental Acceptance within a Trauma-Exposed Community Sample.

Authors: Marcel O. Bonn-Miller, Anka A. Vujanovic, Michael P. Twohig, Johnna L. Medina, Jennifer L. Huggins Published in Mindfulness 25 May 2010   Abstract We examined the role of non-judgmental…

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors: Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, et al
Molecular Cancer Therapeutics, January 2010

The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma. It has bee…